Yingli Pharma’s YL-17231 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
US-based Yingli Pharma, a company dedicated to developing drugs for both the China and US...
NHSA Issues 2023 Guidelines: Enhancing Basic Medical Insurance and Major Illness Coverage
The National Healthcare Security Administration (NHSA) has released the “Notice on Ensuring Basic Healthcare Security...
Akeso Biopharma Initiates Phase Ia/Ib Study for TIGIT mAb AK127 in Solid Tumors Combination Therapy
China-based Akeso Biopharma (HKG: 9926) has announced the first patient enrollment in a Phase Ia/Ib...
ACROBiosystems Partners with OBiO Technology to Advance Cell and Gene Therapy
ACROBiosystems Group (SHE: 301080) has announced a partnership with China-based gene therapy specialist OBiO Technology...
Lucence and Innovent Biologics Partner to Enhance Access to Cholangiocarcinoma Treatment in Hong Kong
Singapore-based precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto...
Beijing Balance Medical’s Transcatheter Valve System Enters China’s Innovative Device Review
China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has announced that its transcatheter valve...
Eli Lilly’s Tirzepatide Demonstrates Up to 26.6% Weight Loss in Phase III Obesity Studies
US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has released final results from two...
CDE Issues Guiding Principles for Natural History Research in Rare Disease Drug Development
The Center for Drug Evaluation (CDE) has released the “Guiding Principles for Natural History Research...
Sino Biopharmaceutical Receives NMPA Approval for Biosimilar Herceptin for HER2+ Cancers
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received market approval from the...
CDE Launches Technical Guidelines to Emphasize Patient-Centered Drug Clinical Trials
The Center for Drug Evaluation (CDE) has released a series of Technical Guidelines that encompass...
Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of...
Jiangsu Simcere Pharmaceutical Receives NMPA Approval for Atopic Dermatitis Drug SIM0278
China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received clinical...
Pingshan District and Fosun Pharma Ink Strategic Deal to Boost Biomedical Industry
The People’s Government of Pingshan District in Shenzhen has signed a cooperation framework agreement with...
CanSino Biotechnology Receives NMPA Approval for Tetanus Vaccine CS-2047
China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced that it has received clinical...
SanReno Therapeutics Partners with WuXi STA for Comprehensive R&D and Manufacturing Services
Shanghai-based kidney drug developer SanReno Therapeutics has entered into a partnership with WuXi STA, a...
Chongqing Zhifei Biological Partners with PT Bio Farma for Global Tuberculosis Vaccine Development
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a global cooperation memorandum...
BRL Medicine Inc. Receives IND Approval for CD19-Targeted CAR-T Therapy BRL-301 from CDE
Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...
Bristol-Myers Squibb Q2 2023 Results Miss Estimates, Full-Year Guidance Revised Downward
US pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has released its financial report for the...
Pfizer Announces Leadership Shake-Up with Focus on Oncology R&D
Pfizer Inc., (NYSE: PFE) has announced significant changes in its Research and Development (R&D) leadership....
Roche Group’s H1 2023 Financial Report: Pharmaceuticals Grow While Diagnostics Dip
Swiss pharmaceutical giant Roche Group (SWX: ROG) has released its half-yearly financial report for 2023,...